FDA Clears CT-Based AI for Aortic Assessment and Monitoring

The Food and Drug Administration (FDA) has granted 510(k) clearance for Rapid Aortic, an artificial intelligence (AI)-enabled software for computed tomography (CT) evaluation of the aorta.

RapidAI, the developer of Rapid Aortic, said the adjunctive software may enhance the detection of aortic aneurysms and dissections. Through automated 3D aorta reconstructions and critical measurements, Rapid Aortic facilitates longitudinal monitoring of pertinent anatomical changes as well, according to RapidAI.

Noting the software’s capability to provide identification and tracking of aortic pathology, RapidAI emphasized that the ability of Rapid Aortic to offer 24 guideline-based measurements as well as advanced visualization can significantly improve pre-procedure planning and monitoring.

“Rapid Aortic represents a significant advancement for aortic patient management,” said Trissa Babrowski, M.D., a vascular surgeon at the University of Chicago. “With instant access to every textbook landmark and zonal maximum measurement, advanced visualizations, and robust longitudinal tracking for surveillance, Rapid Aortic empowers physicians to efficiently identify, confidently assess, and diligently monitor every aortic patient within their system.”